Skye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice

Skye Bioscience (SKYE) has received a Nasdaq deficiency notice because its common stock traded below the $1.00 minimum bid price for 30 consecutive business days, risking its Nasdaq Global Market listing. The company has until September 14, 2026, to regain compliance, possibly through a reverse stock split. Spark, TipRanks’ AI Analyst, rates SKYE as Neutral due to weak financial performance and bearish technical signals, despite some positive offsets from recent earnings calls and Phase 2a data.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin